Preprint
Cost-utility analysis of low-dose pioglitazone in a population with prediabetes and a history of stroke and TIA
Abstract
Abstract BACKGROUND Among patients with type 2 diabetes and a history of strokes or transient ischemic attacks, pioglitazone significantly reduces the risk of recurrent stroke. The Insulin Resistance Intervention in Stroke (IRIS) trial found that pioglitazone also reduced the risks of stroke or transient ischemic attacks and new-onset diabetes among patients with insulin resistance. As reported by our previous work, the low-dose pioglitazone …
Authors
Yuan F; Spence JD; Tarride J-E
DOI
10.1101/2023.11.01.23297949
Preprint server
medRxiv